FDA Approves Anacor Pharmaceuticals, Inc.’ KERYDIN™ (Tavaborole) Topical Solution, 5% For The Treatment Of Onychomycosis Of The Toenails

Published: Jul 08, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States, according to Podiatry Today.

“We are pleased to announce the FDA approval of KERYDIN, which provides an important new topical treatment option for the millions of people in the United States who are infected with onychomycosis of the toenails,” said Paul Berns, Chief Executive Officer of Anacor Pharmaceuticals. “We expect to launch KERYDIN in the U.S., either alone or with a partner, as early as the end of this quarter.”

Help employers find you! Check out all the jobs and post your resume.

Back to news